AbbVie announced that the EC has approved SKYRIZI (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque psoriasis… read more.
Novo Nordisk Pharma Co., Ltd. (Japan) announced an adaptation to the existing approval for its long-acting human growth hormone analog formulation “Sogrua” (generic name: Somapsitan (genetically modified)). The… read more.
Gilead Sciences announced that the EC has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast… read more.
Novocure announced topline results from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM) at the start… read more.
Arrowhead Pharmaceuticals, Inc. announced that the European Commission (EC) has formally granted marketing authorization for Redemplo (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet… read more.
The Ministry of Health, Labour and Welfare in Japan has granted approval for Sarclisa (isatuximab) subcutaneous (SC) formulation in combination with approved standard-of-care regimens for the treatment of… read more.
Incyte Biosciences Japan G.K. announced that Japan’s MHLW has approved Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell… read more.
Merck, known as MSD outside of the United States and Canada, announced that the FDA has approved an expanded indication for Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to include… read more.
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces results from the pivotal Phase II registration study of fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (“ICC”) will be presented… read more.
Nurix Therapeutics announced updated clinical data from the Company’s ongoing NX-5948-301 Phase 1a/b clinical trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic… read more.
Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the ConfIdeS Phase 3 abstract titled “Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared to… read more.
Long-term survival modeling of Boehringer Ingelheim’s oral preferential PDE4B inhibitor, nerandomilast, predicts the therapy could extend survival by up to 5.4 years in adults with idiopathic pulmonary fibrosis… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
